Resapp Health : Appendix 3B and Issue of Cleansing Prospectus

5b185d28-9084-4b4f-9930-9a5ce9686a3f.pdf

29 April 2016

Company Announcements Office Australian Securities Exchange 10th Floor

20 Bond Street

SYDNEY NSW 2000

Dear Sir

APPENDIX 3B AND ISSUE OF CLEANSING PROSPECTUS

Further to the announcement dated 20 April 2016, ResApp Health Limited (ASX: RAP) ("Company") advises that it has issued 62,500,000 Shares at $0.20 having raised $12.5 million from institutional and sophisticated investors.

The Company has also issued 1,016,250 Advisory Shares together with 4,500,000 Advisory Options (exercisable at $0.28, expiring 29 April 2019, escrowed 12 months from issue) and 1,866,667 Advisory Options (exercisable at $0.30 (previously incorrectly noted at $0.3675 due to a clerical error in the capital raising mandate letter), expiring 29 April 2019, escrowed 12 months from issue).

An Appendix 3B for the issue of these securities is attached. The Company has also issued a cleansing prospectus ("Prospectus") pursuant to Section 708A(11) of the Corporations Act. The purpose of the Prospectus is to remove any trading restrictions in relation to the securities issued pursuant to placement.

Yours faithfully

Nicki Farley Company Secretary ResApp Health Limited ABN 51 094 468 318

Level 24, 44 St Georges Tce, Perth WA 6000

T [phone] E [e-mail] W www.resapphealth.com.au

Appendix 3B

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

New issue announcement, application for quotation of additional securities‌ and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

RESAPP HEALTH LIMITED

ABN

51 094 468 318

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	Ordinary Fully Paid Shares Unlisted Options
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	63,516,250 Shares 6,366,667 Unlisted Options
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	63,516,250 Shares 4,500,000 Unlisted Options (exercisable at $0.28, expiring 29 April 2019) escrowed for 12 months to 29 April 2017. 1,866,667 Unlisted Options (exercisable at $0.30, expiring 29 April 2019) escrowed for 12 months to 29 April 2017.

4	Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Shares - Yes Options - will rank equally on conversion
5	Issue price or consideration	62,500,000 Shares issued at $0.20 per Share pursuant to the Company's Placement. 6,366,667 Unlisted Options and 1,016,250 Shares issued as fees for capital raising services provided in respect of the Company's Placement.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Funds raised will be used to expedite US FDA approval for the adult diagnostic test, expand US market opportunity into in-clinic use, expand global opportunity into Europe and Asia, and accelerate development of respiratory disease management tools.
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2015

+ See chapter 19 for defined terms.

Appendix 3B Page 2 04/03/2013

6c	Number of +securities issued without security holder approval under rule 7.1	Nil
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	-
6f	Number of +securities issued under an exception in rule 7.2	-
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	Not applicable
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements	Listing Rule 7.1 - 12,125,273 Listing Rule 7.1A - 58,005,460
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	29 April 2016
Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	530,508,353	Fully paid ordinary shares